Merck's $6.7 Billion Terns Deal: Strategic Repositioning in the Face of Keytruda's Expiration
Merck announced on March 25, 2026, that it has entered into a definitive agreement to acquire Terns Pharmaceuticals, Inc. for $53.00 per share in cash, representing an approximate equity value of $6.7 billion, or $5.7 billion net of acquired cash. The transaction, which has received approval from both companies' boards of directors, reflects Merck's aggressive strategy to fortify its oncology pipeline and offset anticipated revenue declines from its flagship cancer immunotherapy Keytruda as patent protection expires.
The acquisition premium is substantial: the offer represents a 31% premium to Terns' 60-day volume-weighted average stock price and a 42% premium to the 90-day volume-weighted average price as of March 24, 2026. This valuation signals Merck's confidence in the strategic value of Terns' lead asset and the broader market recognition of the company's potential. Terns' stock price has appreciated sixfold over the past six months, driven by investor enthusiasm surrounding the blockbuster potential of its leukemia drug and speculation regarding acquisition interest from larger pharmaceutical players.
TERN-701: A Differentiated Asset in a Competitive Landscape
The crown jewel of this acquisition is TERN-701, an oral allosteric BCR::ABL1 tyrosine kinase inhibitor (TKI) currently in Phase 1/2 clinical evaluation. The compound is being assessed in the CARDINAL trial (NCT06163430) for patients with Philadelphia chromosome-positive chronic phase chronic myeloid leukemia (CML) who have experienced treatment failure, suboptimal response, or treatment intolerance following at least one prior TKI therapy. This patient population represents a significant unmet medical need within the hematologic malignancy space.
TERN-701 has demonstrated encouraging efficacy and safety signals in recent trial data while offering a critical advantage over existing therapies: greater convenience for patients through its oral formulation. In a market where patient adherence and quality of life represent key differentiators, this attribute positions the compound as a potentially best-in-class candidate. According to the American Cancer Society, CML accounts for approximately 15% of all new leukemia cases, with an estimated 9,650 new diagnoses expected in 2026, establishing a meaningful addressable patient population for this therapeutic intervention.
Terns is preparing to initiate late-stage trials toward the end of 2026 or in early 2027, positioning TERN-701 for potential regulatory submissions within a reasonable timeframe. This development trajectory aligns with Merck's strategic imperative to accelerate the advancement of its oncology portfolio.
Strategic Context: Keytruda's Patent Cliff and Portfolio Diversification
This acquisition must be understood within the broader context of Merck's pharmaceutical portfolio dynamics. Keytruda, the company's blockbuster PD-1 checkpoint inhibitor, has generated substantial revenues across multiple oncology indications and represents a cornerstone of Merck's commercial success. However, the imminent expiration of Keytruda's patent protection poses a significant revenue headwind that Merck must actively mitigate through strategic acquisitions and internal pipeline development.
The Terns acquisition follows other recent high-profile purchases, including the acquisitions of Verona Pharma and Cidara Therapeutics, demonstrating Merck's systematic approach to portfolio renewal. Robert M. Davis, Merck's chairman and chief executive officer, stated that the acquisition
